Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Other Operating Expenses (2019 - 2025)

Cyclerion Therapeutics has reported Other Operating Expenses over the past 5 years, most recently at $1.3 million for Q2 2025.

  • Quarterly results put Other Operating Expenses at $1.3 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $1.3 million (changed N/A YoY), and the annual figure for FY2023 was $3.3 million, changed.
  • Other Operating Expenses for Q2 2025 was $1.3 million at Cyclerion Therapeutics, down from $3.3 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CYCN hit a ceiling of $3.3 million in Q3 2023 and a floor of -$881000.0 in Q2 2021.
  • Median Other Operating Expenses over the past 3 years was $1.3 million (2025), compared with a mean of $1.2 million.